A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 11, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2026

Conditions

Prostate Cancer

Interventions

DRUG

HRS-1167 tablets

DRUG

Abiraterone Acetate tablets（II）

DRUG

Prednisone Acetate tablets

Trial Locations (2)

RECRUITING

The First Affiliated Hospital Of Anhui Medical University, Hefei

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY